Clinical trials: Body Weight Control
Obesity
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: overweight with high blood pressure or high cholesterol or obese The safety of this treatment will also be studied
- Trial name
- NCT00388609
- Testing
- BMS-646256
- Where
- 10 sites in United States
- Volunteers
- 705 people
- Sponsor
- Bristol-Myers Squibb
Obesity
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
- Trial name
- NCT00554216
- Testing
- VI-0521
- Where
- 5 sites in United States
- Volunteers
- 1,267 people
- Sponsor
- VIVUS LLC
Obesity, Overweight
Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)
The purpose of this study is to evaluate the effect of SCH 497079 on weight in obese and overweight participants. The primary measure of effectiveness is the change in body weight during treatment.
- Conditions
- Obesity, Overweight, Body Weight
- Trial name
- NCT00642993
- Testing
- SCH 497079
- Volunteers
- 401 people
- Sponsor
- Merck Sharp & Dohme LLC
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Healthy Participants
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
The purpose of this study is to evaluate the safety, tolerability, and drug level of Pegbelfermin in healthy overweight and obese Chinese and Korean participants.
- Trial name
- NCT04649710
- Testing
- BMS-986036
- Where
- 2 sites in China, South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Metabolism and Nutrition Disorder, Obesity
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.
- Trial name
- NCT01789086
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
VK2735 for Weight Management Phase 2
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who…
- Trial name
- VENTURE (NCT06068946)
- Testing
- VK2735
- Where
- 20 sites in United States
- Volunteers
- 176 people
- Sponsor
- Viking Therapeutics, Inc.
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387282
- Testing
- Anamorelin HCl
- Where
- 46 sites in United States, Australia and 5 more
- Volunteers
- 495 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Obese, Overweight Adults
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults.
- Conditions
- Obese, Overweight Adults, Obese Adults, Body Weight Control
- Trial name
- NCT07363148
- Testing
- MB-1
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Arrae
Diabetes, Diabetes Mellitus, Type 2
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N…
- Trial name
- LEONCET2 (NCT00657930)
- Testing
- insulin detemir
- Where
- Hungary
- Volunteers
- 2,289 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type II, Obesity
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
An exploratory study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus
- Trial name
- NCT03596177
- Testing
- MEDI0382
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- MedImmune LLC
Leptin Receptor Deficiency Obesity
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the…
- Trial name
- NCT03287960
- Testing
- Setmelanotide
- Where
- 6 sites in Canada, France and 4 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Muscle Wasting, Obesity & Overweight
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more…
- Conditions
- Muscle Wasting, Obesity & Overweight, Obesity
- Trial name
- OBA (NCT07411378)
- Testing
- BIO101, Semaglutide
- Volunteers
- 164 people
- Sponsor
- Biophytis
Overweight or Obesity
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for…
- Trial name
- NCT05997576
- Testing
- TG103 22.5 mg
- Where
- China
- Volunteers
- 675 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Efficacy of Electrical Vestibular Nerve Stimulation (VeNS) in the Management of Obesity: A Randomized Clinical Trial
The aim of this study is to observe the efficacy of electrical vestibular nerve stimulation in the management of obesity. Allocation: Active device (participants act as their own self-control) Endpoint classification: Efficacy…
- Trial name
- NCT05275790
- Testing
- Vestal device, Lifestyle intervention
- Where
- India
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Overweight, Healthy Subjects
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects
Primary Objective: To assess the safety and tolerability of SAR441255 after ascending single subcutaneous (SC) doses Secondary Objectives: To assess the pharmacokinetic parameters of SAR441255 in plasma after ascending single SC…
- Trial name
- NCT04521738
- Testing
- SAR441255
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sanofi
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH. The study may be conducted in up to 2 dosing cohorts.
- Trial name
- NCT04004325
- Testing
- FT-4101, Deuterated Water
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Forma Therapeutics, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company